Recent developments include the announcement of a merger with Zura Bio to form Zura Bio Limited and changes in institutional investor positions.

• On June 17, 2022, JATT Acquisition and Zura Bio announced a merger to form Zura Bio Limited, indicating a strategic business combination [N3].
• On February 6, 2023, Hudson Bay Capital Management increased its position in JATT Acquisition Corp., reflecting investor interest [N1].
• On February 2, 2023, Magnetar Financial reduced its stake in JATT Acquisition Corp., indicating some investor repositioning [N2].
• The company filed its 10-Q on August 12, 2026, disclosing financial results and risk factors consistent with its IPO prospectus [S1].

The business combination with Talawar Tx Inc. and the concurrent PIPE financing provide JATT with capital and a platform to pursue growth opportunities through the combined company. The adoption of equity incentive plans may support talent retention and alignment. Institutional investor interest, as evidenced by recent position changes, indicates some market engagement with the company’s prospects.

Risks include the early stage of clinical development of the combined company's product candidates, reliance on third parties, regulatory approval challenges, and market volatility. The SPAC structure entails execution risk related to completing the business combination and integrating the combined entity. The company reported a net loss and limited operational history, which may impact investor confidence.

As a SPAC, JATT's moat is primarily derived from its ability to identify and consummate a business combination with a target company. The moat of the combined entity will depend on the underlying business of Talawar Tx Inc., which is not detailed in the current disclosures. The SPAC structure itself does not confer a competitive advantage beyond the transaction execution capabilities and sponsor expertise.

• Execution Risk: The ability to complete the business combination is subject to shareholder approvals, regulatory conditions, and customary closing conditions. Failure to satisfy these could delay or prevent the transaction.
• Clinical and Regulatory Risk: The combined company’s product candidates are in early clinical development stages, facing risks related to regulatory approvals, clinical trial outcomes, and intellectual property protection.
• Market and Competitive Risk: The company faces competition within its industry and is subject to market conditions, economic factors, and geopolitical developments that could impact performance.
• Financial Risk: The company reported a net loss and has limited financial history. Maintaining liquidity and managing expenses post-combination are critical.

• JATT II Acquisition Corp. is a Cayman Islands exempted company operating as a special purpose acquisition company (SPAC).
• The company completed its initial public offering (IPO) on April 20, 2026, issuing 6 million ordinary shares at $10.00 per share, raising gross proceeds of $60 million.
• Simultaneously with the IPO, a private placement of 300,000 shares was completed, raising an additional $3 million.
• Proceeds from the IPO and private placement were deposited in a trust account for the benefit of public shareholders as of April 20, 2026.
• On June 29, 2026, JATT entered into a Business Combination Agreement to merge with Talawar Tx Inc., with JATT surviving as a wholly-owned subsidiary of the combined company.
• The combined company will continue to operate through Talawar Tx Inc.
• The Business Combination Agreement includes customary representations, warranties, covenants, and conditions to closing, including shareholder approvals and regulatory compliance.
• Concurrent with the Business Combination Agreement, a PIPE financing was arranged for $225 million at $10.00 per share, subject to customary closing conditions.
• The company has an Equity Incentive Plan and Employee Stock Purchase Plan to be adopted upon closing of the business combination.
• As of June 30, 2026, the company reported current assets of approximately $1.83 million and current liabilities of approximately $0.35 million, resulting in a current ratio of 5.19.
• Net income for the quarter ending June 30, 2026, was a loss of approximately $305,553.
• Basic and diluted earnings per share for the quarter ending March 31, 2026, were both -$0.05 per share.
• Risk factors disclosed include the early stage of clinical development of the company’s product candidates, reliance on third parties, regulatory approval risks, competition, and market conditions.
• The company’s filings caution that forward-looking statements are subject to risks and uncertainties and that actual results may differ materially.
• Recent news includes the announcement of the merger with Zura Bio to form Zura Bio Limited, and changes in institutional investor positions such as Hudson Bay Capital increasing its stake and Magnetar Financial reducing its stake.